Invention Grant
- Patent Title: Recombinant antigen derived from Zika virus E protein and use thereof
-
Application No.: US16708797Application Date: 2019-12-10
-
Publication No.: US11291714B2Publication Date: 2022-04-05
- Inventor: You-Jin Kim , Hyun Ju In , HeeJi Lim , Sun-Dong Jang , Jung-Sik Yoo , Gyung Tae Chung
- Applicant: Korea Center For Disease Control And Prevention
- Applicant Address: KR Chungcheongbuk-do
- Assignee: Korea Center For Disease Control And Prevention
- Current Assignee: Korea Center For Disease Control And Prevention
- Current Assignee Address: KR Chungcheongbuk-do
- Agency: Servilla Whitney LLC
- Priority: KR10-2018-0160420 20181212
- Main IPC: A61K39/12
- IPC: A61K39/12 ; C07K14/005 ; C12N7/00 ; C07K16/10 ; C12N15/70 ; C12N1/20 ; A61K39/00 ; C12R1/19
Abstract:
The present invention relates to a recombinant antigen derived from Zika virus E protein and use thereof. Specifically, the present invention provides a polynucleotide encoding Zika virus E protein domain III alone or repeatedly three times, a recombinant plasmid vector comprising the polynucleotide, and a DNA vaccine composition that may induce an immune response to Zika virus by expressing a Zika virus antigen protein effectively. In addition, the present invention provides a neutralizing antibody against Zika virus obtained using the polynucleotide and a method for preparing the neutralizing antibody.
Public/Granted literature
- US20200230227A1 Recombinant Antigen Derived From Zika Virus E Protein And Use Thereof Public/Granted day:2020-07-23
Information query
